Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction

Thomas P. Kraehenbuehl, Lino S. Ferreira, Alison M. Hayward, Matthias Nahrendorf, André J. van der Vlies, Eliza Vasile, Ralph Weissleder, Robert Langer, Jeffrey A. Hubbell

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

We present use of a synthetic, injectable matrix metalloproteinase (MMP)- responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries to the heart in a rat model. The gel was found to substitute the degrading extracellular matrix in the infarcted myocardium of rats and to promote structural organization of native endothelial cells, while some of the delivered hESC-derived vascular cells formed de novo capillaries in the infarct zone. Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d ejection fraction, + ∼7%, P < 0.001; 6 wk ejection faction, + ∼12%, P < 0.001). Elevation in vessel density was observed in response to treatment, which may be due in part to elevations in human (donor)-derived cytokines EGF, VEGF and HGF (1 d). Thus, a clinically relevant matrix for dual delivery of vascular cells and drugs may be useful in engineering sustained tissue preservation and potentially regenerating ischemic cardiac tissue.

Original languageEnglish
Pages (from-to)1102-1109
Number of pages8
JournalBiomaterials
Volume32
Issue number4
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Tissue Preservation
Stem cells
Grafts
Blood Vessels
Rats
Myocardial Infarction
Tissue
Transplants
Heart Injuries
Thymosin
Injections
Hydrogel
Endothelial cells
Matrix Metalloproteinases
Tissue engineering
Epidermal Growth Factor
Hydrogels
Scaffolds
Magnetic resonance imaging
Vascular Endothelial Growth Factor A

Keywords

  • Biomimetic material
  • Cardiac tissue engineering
  • Hydrogel
  • Matrix metalloproteinase
  • Stem cell
  • Vascular grafts

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Kraehenbuehl, T. P., Ferreira, L. S., Hayward, A. M., Nahrendorf, M., van der Vlies, A. J., Vasile, E., ... Hubbell, J. A. (2011). Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials, 32(4), 1102-1109. https://doi.org/10.1016/j.biomaterials.2010.10.005

Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. / Kraehenbuehl, Thomas P.; Ferreira, Lino S.; Hayward, Alison M.; Nahrendorf, Matthias; van der Vlies, André J.; Vasile, Eliza; Weissleder, Ralph; Langer, Robert; Hubbell, Jeffrey A.

In: Biomaterials, Vol. 32, No. 4, 01.02.2011, p. 1102-1109.

Research output: Contribution to journalArticle

Kraehenbuehl, TP, Ferreira, LS, Hayward, AM, Nahrendorf, M, van der Vlies, AJ, Vasile, E, Weissleder, R, Langer, R & Hubbell, JA 2011, 'Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction', Biomaterials, vol. 32, no. 4, pp. 1102-1109. https://doi.org/10.1016/j.biomaterials.2010.10.005
Kraehenbuehl TP, Ferreira LS, Hayward AM, Nahrendorf M, van der Vlies AJ, Vasile E et al. Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials. 2011 Feb 1;32(4):1102-1109. https://doi.org/10.1016/j.biomaterials.2010.10.005
Kraehenbuehl, Thomas P. ; Ferreira, Lino S. ; Hayward, Alison M. ; Nahrendorf, Matthias ; van der Vlies, André J. ; Vasile, Eliza ; Weissleder, Ralph ; Langer, Robert ; Hubbell, Jeffrey A. / Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. In: Biomaterials. 2011 ; Vol. 32, No. 4. pp. 1102-1109.
@article{2bc2283b532445a9825dd8996c49ec9b,
title = "Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction",
abstract = "We present use of a synthetic, injectable matrix metalloproteinase (MMP)- responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries to the heart in a rat model. The gel was found to substitute the degrading extracellular matrix in the infarcted myocardium of rats and to promote structural organization of native endothelial cells, while some of the delivered hESC-derived vascular cells formed de novo capillaries in the infarct zone. Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d ejection fraction, + ∼7{\%}, P < 0.001; 6 wk ejection faction, + ∼12{\%}, P < 0.001). Elevation in vessel density was observed in response to treatment, which may be due in part to elevations in human (donor)-derived cytokines EGF, VEGF and HGF (1 d). Thus, a clinically relevant matrix for dual delivery of vascular cells and drugs may be useful in engineering sustained tissue preservation and potentially regenerating ischemic cardiac tissue.",
keywords = "Biomimetic material, Cardiac tissue engineering, Hydrogel, Matrix metalloproteinase, Stem cell, Vascular grafts",
author = "Kraehenbuehl, {Thomas P.} and Ferreira, {Lino S.} and Hayward, {Alison M.} and Matthias Nahrendorf and {van der Vlies}, {Andr{\'e} J.} and Eliza Vasile and Ralph Weissleder and Robert Langer and Hubbell, {Jeffrey A.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2010.10.005",
language = "English",
volume = "32",
pages = "1102--1109",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction

AU - Kraehenbuehl, Thomas P.

AU - Ferreira, Lino S.

AU - Hayward, Alison M.

AU - Nahrendorf, Matthias

AU - van der Vlies, André J.

AU - Vasile, Eliza

AU - Weissleder, Ralph

AU - Langer, Robert

AU - Hubbell, Jeffrey A.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - We present use of a synthetic, injectable matrix metalloproteinase (MMP)- responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries to the heart in a rat model. The gel was found to substitute the degrading extracellular matrix in the infarcted myocardium of rats and to promote structural organization of native endothelial cells, while some of the delivered hESC-derived vascular cells formed de novo capillaries in the infarct zone. Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d ejection fraction, + ∼7%, P < 0.001; 6 wk ejection faction, + ∼12%, P < 0.001). Elevation in vessel density was observed in response to treatment, which may be due in part to elevations in human (donor)-derived cytokines EGF, VEGF and HGF (1 d). Thus, a clinically relevant matrix for dual delivery of vascular cells and drugs may be useful in engineering sustained tissue preservation and potentially regenerating ischemic cardiac tissue.

AB - We present use of a synthetic, injectable matrix metalloproteinase (MMP)- responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries to the heart in a rat model. The gel was found to substitute the degrading extracellular matrix in the infarcted myocardium of rats and to promote structural organization of native endothelial cells, while some of the delivered hESC-derived vascular cells formed de novo capillaries in the infarct zone. Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d ejection fraction, + ∼7%, P < 0.001; 6 wk ejection faction, + ∼12%, P < 0.001). Elevation in vessel density was observed in response to treatment, which may be due in part to elevations in human (donor)-derived cytokines EGF, VEGF and HGF (1 d). Thus, a clinically relevant matrix for dual delivery of vascular cells and drugs may be useful in engineering sustained tissue preservation and potentially regenerating ischemic cardiac tissue.

KW - Biomimetic material

KW - Cardiac tissue engineering

KW - Hydrogel

KW - Matrix metalloproteinase

KW - Stem cell

KW - Vascular grafts

UR - http://www.scopus.com/inward/record.url?scp=78649446021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649446021&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2010.10.005

DO - 10.1016/j.biomaterials.2010.10.005

M3 - Article

VL - 32

SP - 1102

EP - 1109

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 4

ER -